Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10016


A Safety and Efficacy trial of aerosol Interferon-gamma treatment in Pulmonary Fibrosis


Inclusion Criteria: - Patients diagnosed with IPF based on accepted criteria within 30 months prior to screening - Age 20-70 - A failed trial of prednisone with or without cyclophosphamide/ azathioprine - Patient taking 0-15mg prednisone or the equivalent for 28 days prior to study enrollment and willing to remain on that same dose of corticosteroid - FVC >= 50% and <= 90% of predicted baseline value at screening - PaO2 > 60 mm Hg at rest on room air - Patient able to understand and willing to sign a written informed consent and willing to comply with all requirements of the study protocol including: - Patient fits criteria for research bronchoscopy and is willing to undergo procedure - Patient able to have medication administered three times per week at the GCRC unit at Bellevue Hospital Exclusion Criteria: - No adequate treatment trial with prednisone, cyclophosphamide, or azathioprine - patient unwilling or unable to undergo research bronchoscopy - Patient with known asthma or severe COPD - Patient requiring oxygen therapy for maintenance of adequate arterial oxygenation - Patient with hypersensitivity to study medication or other component medication - Patient with known severe cardiac disease, severe peripheral vascular disease or seizure disorder which may be exacerbated by study drug administration (contraindications to drug administration as per package insert). - Pregnant or lactating. Females of child-bearing age will be required to have negative pregnancy test and be required to use accepted form of birth control (abstinence for study duration is the preferred method). - Evidence of active infection within one week prior to treatment - Any condition, other than IPF, which is likely to result in the death of the patient within one year from study enrollment - Abnormal serum laboratory values including: 1. Liver function above specified limits: total bilirubin > 1.5 X upper limits of normal, alanine amino transferase > 3X upper limit of normal, alkaline phosphatase < 3X upper limit of normal, albumin < 3.0 at screening. 2. CBC outside specified limits: WBC < 2,500/mm3, hematocrit <30 or >59, platelets < 100,000/mm3. 3. Creatinine > 1.5X upper limits normal at screening - Drugs for therapy for pulmonary fibrosis, excluding corticosteroids/cyclophosphamide/azathioprine, within the previous six months - Prior therapy with any class of interferon medication - Investigational therapy for any indication within the last 28 days



Primary Contact:

Principal Investigator
Rany Condos, MD
NYU School of Medicine

Backup Contact:


Location Contact:

New York, New York 10016
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.